Molecular targeted therapies for metastatic RCC, such as vascular endothelial growth factor (VEGF)–targeting tyrosine kinase inhibitors (TKIs)—and inhibitors of the mechanistic target of rapamycin have been extensively tested as adjuvant therapies aiming to eliminate micro-metastasis that may be present at the time of the nephrectomy [6,7,11,12,13,14,15,16,17,18,19,20,21]. The gene discussed is VEGFA; the disease is renal cell carcinoma.